中国P站

Bcs-based biowaiver; Generic drugs; Immediate-release tablets; Antihypertensive medication; In vitro dissolution; Bioequivalence; Regulatory approval; Bcs class i; Waiver justification; Clinical pharmacology

Introduction

The Biopharmaceutics Classification System (BCS) provides a scientific framework for classifying drug substances based on their aqueous solubility and intestinal permeability. Regulatory agencies such as the US FDA and EMA allow biowaivers—exemptions from in vivo bioequivalence studies—for certain drug products that meet specific criteria under BCS guidelines [1-5]. For immediate-release (IR) oral formulations, especially BCS Class I drugs (high solubility, high permeability), in vitro dissolution data can serve as a surrogate for in vivo performance. This approach reduces the need for costly and time-consuming human trials while maintaining product quality and safety. This study presents a scientific justification for granting a BCS-based biowaiver for a generic immediate-release antihypertensive tablet, based on physicochemical characteristics, dissolution performance, and regulatory compliance [6-10].

Discussion

The active pharmaceutical ingredient (API) in this formulation belongs to BCS Class I, as it meets solubility criteria across a pH range of 1 to 6.8 and exhibits high permeability as demonstrated in human and animal studies. The in vitro dissolution profile of the generic product was evaluated using USP Apparatus II in multiple media, showing greater than 85% release within 15 minutes—a regulatory benchmark for BCS-based biowaivers. The formulation also met criteria for excipient similarity, dosage form sameness, and stability. When compared with the reference product, the generic demonstrated rapid and complete dissolution, indicating minimal risk of in vivo bioinequivalence. Risk assessment tools and decision trees from WHO and ICH were applied to strengthen the biowaiver justification. The adoption of this approach can accelerate market entry and reduce development costs for generic manufacturers, facilitating greater access to affordable antihypertensive therapy.

Conclusion

This study supports the BCS-based biowaiver for a generic immediate-release antihypertensive tablet by demonstrating adequate solubility, permeability, and dissolution. Regulatory approval through this pathway can streamline drug development without compromising quality or efficacy, ultimately benefiting public health by enhancing generic drug availability.

References

1. Li Y, Zhang L, Wang Y (2022) Nat Commun 13

   , ,

2. Zhang D, Luo G, Ding X, Lu C (2012) . Acta Pharm Sin B 2: 549-561.

3. Sahu A, Mishra J, Kushwaha N. (2022) Comb Chem High Throughput Screen 25: 1818-1837.

   , ,

4. Sahu A, Mishra J, Kushwaha N. (2022) Comb Chem High Throughput Screen 25: 1818-1837.

   , ,

5. Bosch TM, Meijerman I, Beijnen JH (2006) . Clin Pharmacokinet 45: 253-285.

   , ,

6. Bosma PJ, Chowdhury JR, Bakker C (1995) N Engl J Med 333: 1171-1175.

   , ,

7. Sapoval N, Aghazadeh A, Nute MG (2022) Nat Commun 13

   , ,

8. Kim H, Kim E, Lee I, Bae B, Park M, et al. (2020) Biotechnol Bioprocess Eng 25: 895-930.

   , ,

9. Miljkovi膰 F, Rodríguez-Pérez R, Bajorath J (2021) ACS Omega 6: 33293-33299.

   , ,

10. Adam G, Rampášek L, Safikhani Z, Smirnov P, Haibe-Kains B, et al. (2020) NPJ Precis Oncol 4

    , ,